ArticleFuture oncology (London, England)2025
Fibrinolysis markers as predictive indicators of neoadjuvant chemotherapy efficacy in ovarian cancer patients.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsOvarian cancer (OC) is a prevalent gynecological malignancy with high mortality due to its asymptomatic progression and advanced stage at diagnosis. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is beneficial for patients unsuitable for primary debulking surgery (PDS). Effective markers for assessing NACT outcomes could significantly aid clinical decision-making and personalized treatment strategies. PATIENTS &
methodsIn this retrospective study, we examined fibrinolytic markers, including D-dimer, fibrinogen (FIB), and fibrinogen degradation products (FDP), among 167 OC patients and 110 healthy controls. Plasma levels of these markers were measured before and after four NACT cycles in OC patients, and receiver operating characteristic (ROC) analysis was conducted to evaluate their diagnostic and predictive value.
resultsOC patients exhibited significantly elevated baseline levels of D-dimer, FIB, and FDP compared to healthy controls. Post-NACT measurements showed that responders had a substantial decrease in these markers, while non-responders showed minimal changes. ROC analysis confirmed the diagnostic accuracy of D-dimer, FIB, and FDP, with high sensitivity and specificity for predicting NACT effectiveness.
conclusionD-dimer, FIB, and FDP are elevated in OC patients and demonstrate a potential role as noninvasive markers for assessing NACT efficacy, offering valuable insights for treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.